| Project/Area Number |
22591447
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
YASUNAGA Masahiro 独立行政法人国立がん研究センター, 臨床開発センター, ユニット長 (80450576)
|
|---|
| Research Collaborator |
MATSUMURA Yasuhiro 独立行政法人国立がん研究センター, 臨床開発センター, 分野長 (90209619)
MANABE Shino 独立行政法人理化学研究所, 伊藤細胞制御化学, 専任研究員 (60300901)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2011: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2010: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
|
|---|
| Keywords | 抗体デリバリー / 抗体 / ADC / DDS / 間質バリア / 膵臓がん / 悪性リンパ種 / SN-38 / in vivoイメージング / 抗体インタナリゼーション / 悪性リンパ腫 / 抗体インターナリゼーション |
|---|
| Research Abstract |
In pancreatic cancer as a refractory solid tumor, tumor stromal barrier interferes with antibody-delivery. To improve the delivery and maximize the therapeutic effect of antibody drug conjugate (ADC) against such tumors, it is important to determine the most appropriate drug design e.g. combination of the anti-stroma antibody and the linker for the drug-release outside the cells. On the other hand, cell-targeting ADC is effective against malignant lymphoma as a stroma-poor tumor without the interference of antibody-delivery. In this type of ADC, an antibody having a high cell-internalization efficacy should be selected.
|
